Drug Trial Radar · NCT06513312
Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)
Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
268
Actual
Start
Oct 7, 2024
Primary completion
May 28, 2026
Study completion Nov 2028
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Jul 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goals of this clinical study are to learn more about the study drug lenacapavir (LEN), by comparing the consistent and continuous use of LEN and emtricitabine/tenofovir disoproxil fumarate (coformulated; Truvada®) (F/TDF), then by observing the safety of LEN and F/TDF, evaluating the acceptability of LEN injections and oral F/TDF, and observe how LEN moves throughout the body in people who would benefit from pre-exposure prophylaxis (PrEP). The primary objective of this study is to compare LEN and F/TDF consistent and continuous use among people who would benefit from PrEP.
Conditions
- Pre-Exposure Prophylaxis of HIV Infection
Interventions
Lenacapavir InjectionDrug
Administered subcutaneously
Lenacapavir TabletDrug
Administered orally
Emtricitabine/tenofovir disoproxil fumarate (F/TDF)Drug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with LEN and F/TDF Persistence through 52 WeeksTime frame: Up to Week 52
Locations
14 sites in 2 countries. Site status is shown where the registry gives one.
Hopital Avicenne
Bobigny, France
Hopital Europeen Marseille
Marseille, France
CHU Nice Archet
Nice, France
Hopital Saint Louis - Assistance Publique des Hopitaux de Paris
Paris, France
APHP Hopital Saint-Antoine
Paris, France
APHP Bichat Claude-Bernard Hospital
Paris, France
University Hospitals Birmingham NHS Foundation Trust, Birmingham Heartlands Hospital
Birmingham, United Kingdom
Clinical Research Facility, University Hospitals Sussex NHS Foundation Trust
Brighton, United Kingdom
Axess Sexual Health, Liverpool University Hospitals NHS Trust
Liverpool, United Kingdom
Grahame Hayton Unit, Ambrose King Centre, Royal London Hospital, Barts Health NHS Trust
London, United Kingdom
Homerton Healthcare NHS Foundation Trust, Homerton University Hospital
London, United Kingdom
Caldecot Centre, Kings College Hospital, Kings College Hospital NHS Foundation Trust
London, United Kingdom
Chelsea and Westminster Hospital NHS Foundation Trust, Clinical Research Facility, Chelsea and Westminster Hospital
London, United Kingdom
Manchester University NS Foundation Trust
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.